Skip to main content Accessibility help
×
Home
  • Print publication year: 2008
  • Online publication date: August 2009

18 - Symptomatic therapies and supportive care issues

Summary

Introduction

The supportive care of cancer patients routinely involves management of multiple symptoms as well as neuropsychiatric disorders associated with cognitive dysfunction, notably delirium, but also in some instances depression. Cancer therapies themselves (especially medications) can cause or exacerbate cognitive dysfunction. Cognitive disorders of all types are the second most common psychiatric disorders experienced by cancer patients after mood disorders (Derogatis et al., 1983). Patients in particular settings and stages of the disease continuum are at particular risk for cognitive impairment, with potential implications for prognosis. The boundaries between these disorders are not always distinct, which complicates accurate diagnosis and treatment. Co-morbidity is common. The stigma associated with mental illness and the physical burdens of caring for affected patients place family members and other caregivers at increased risk for physical and emotional distress. The common cognitive disorders seen in the oncology setting often respond well to treatment. In other cases, palliation of symptoms is possible and individual patients may respond to creative and unconventional medication interventions. Here we discuss common neuropsychiatric syndromes and clinical settings associated with cognitive dysfunction and altered mental status and behavior, interventions, and potential areas for future research.

Delirium

The American Psychiatric Association defines delirium as a syndrome characterized by rapid onset of impaired cognition, and altered consciousness, and it is presumed to be due to one or more physical or disease-related factors (Table 18.1, American Psychiatric Association, 2000; DSM-IV TR).

REFERENCES
Ahles, TA, Saykin, AJ (2002). Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer 3 [Suppl. 3]: S84–S90.
,American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders (4th edn. Text Revision edn. Washington, DC: American Psychiatric Association.
Anthony, JC, LeResche, L, Niaz, Uet al. (1982). Limits of the mini-mental state as a screening test for dementia and delirium among hospital patients. Psychol Med 12(2): 397–408.
Ballon, JS, Feifel, MD (2006). A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 67(4): 554–566.
Boutros, NN, Struve, F (2002). Electrophysiological assessment of neuropsychiatric disorders. Sem Clin Neuropsychiatry 7(1): 30–41.
Breitbart, W, Cohen, KR (1998). Delirium. In Holland, JC (ed.) Psycho-oncology (pp. 564–573). New York: Oxford University Press.
Breitbart, W, Marotta, R, Platt, MMet al. (1996). A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 153(2): 231–237.
Breitbart, W, Rosenfeld, B, Roth, Aet al. (1997). The memorial delirium assessment scale. J Pain Symptom Manage 13(3): 128–137.
Breitbart, W, Gibson, C, Tremblay, A (2002). The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/ caregivers, and their nurses. Psychosomatics 43: 183–194.
Brown, TM (2000). Drug-induced delirium. Sem Clin Neuropsychiatry 5(2): 113–124.
Bruera, E, MacMillan, K, Hanson, J, MacDonald, RN (1989). The Edmonton staging system for cancer pain: preliminary report. Pain 37: 203–209.
Bruera, E, Miller, MJ, Macmillan, K, Kuehn, N (1992a). Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 48(2): 163–166.
Bruera, E, Fainsinger, R, MacEachern, T, Hanson, J (1992b). The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 50(1): 75–77.
Bruera, E, Miller, L, McCallion, J, Macmillan, K, Krefting, L, Hanson, J (1992c). Cognitive failure in patients with terminal cancer: a prospective study. J Pain Symptom Manage 7: 192–195.
Bruera, E, Driver, L, Barnes, EAet al. (2003a). Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 21(23): 4439–4443.
Bruera, E, Strasser, F, Shen, Let al. (2003b). The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage 26(5): 1049–1054.
Bruera, E, Valero, V, Driver, Let al. (2006). Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 24(13): 2073–2078.
Capuron, L, Hauser, P, Hinze-Selch, Det al. (2002). Treatment of cytokine-induced depression. Brain Behav Immunol 16(5): 575–580.
Caraceni, A, Nanni, O, Maltoni, Met al. (2000). Impact of delirium on the short term prognosis of advanced cancer patients. Italian Multicenter Study Group on Palliative Care. Cancer 89(5): 1145–1149.
Carter, GL, Dawson, AH, Lopert, R (1996). Drug-induced delirium. Incidence, management and prevention. Drug Safety 15(4): 291–301.
Cassem, NH, Murray, GB, Lafayette, JM, Stern, TA (2004). Delirious patients. In Stern, T (ed.) Massachusetts General Hospital Handbook of General Hospital Psychiatry (5th edn.). Philadelphia, PA: Mosby.
Crossen, JR, Garwood, D, Glatstein, E, Neuwelt, EA (1994). Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12(3): 627–642.
Del Fabbro, E, Dalal, S, Bruera, E (2006a). Symptom control in palliative care – Part III: Dyspnea. Dyspnea and delirium. J Palliat Med 9(2): 422–436.
Del Fabbro, E, Dalal, S, Bruera, E (2006b). Symptom control in palliative care – Part II: Cachexia/anorexia and fatigue. J Palliat Med 9(2): 409–421.
Derogatis, LR, Morrow, GR, Fetting, J (1983). The prevalence of psychiatric disorders among cancer patients. J Am Med Assoc 249: 751–757.
Dobie, DJ (2002). Depression, dementia, and pseudodementia. Semin Clin Neuropsychiatry 7(3): 170–186.
Fadul, N, Kaur, G, Zhang, T, Palmer, JL, Bruera, E (2007). Evaluation of the Memorial Delirium Assessment Scale (MDAS) for the screening of delirium by means of simulated cases by palliative care health professionals. Support Cancer Care 15(11): 1271–1276.
Fann, JR, Roth-Roemer, S, Burington, BEet al. (2002). Delirium in patients undergoing hematopoietic stem cell transplantation. Cancer 95(9): 1971–1981.
Folstein, MF, Folstein, SE, McHugh, PR (1975). Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3): 189–198.
Franco, K, Litaker, D, Locala, J, Bronson, D (2001). The cost of delirium in the surgical patient. Psychosomatics 42(1): 68–73.
Gagnon, B, Allard, P, Masse, B, DeSerres, M (2000). Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage 19: 412–426.
Gagnon, B, Low, G, Schreier, G (2005). Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci 30(2): 100–107.
Gaudreau, JD, Gagnon, P, Roy, MAet al. (2005). Association between psychoactive medications and delirium in hospitalized patients: a critical review. Psychosomatics 46(4): 302–316.
Homsi, J, Walsh, D, Nelson, KA (2000). Psychostimulants in supportive care. Support Care Cancer 8(5): 385–397.
Inouye, SK (1998). Delirium in hospitalized older patients: recognition and risk factors. J Geriatric Psychiatry Neurol 11(3): 118–125.
Inouye, SK (2000). Prevention of delirium in hospitalized older patients: risk factors and targeted intervention strategies. Ann Med 32(4): 257–263.
Inouye, SK, Dyck, CH, Alessi, CAet al. (1990). Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Int Med 113(12): 941–948.
Kelly, KG, Zisselman, M, Cutillo-Schmitter, Tet al. (2001). Severity and course of delirium in medically hospitalized nursing facility residents. Am J Geriatric Psychiatry 9(1): 72–77.
Lawlor, PG (2002). The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal. Cancer 94(6): 1836–1853.
Lawlor, PG, Gagnon, B, Mancini, ILet al. (2000a). Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Int Med 160(6): 786–794.
Lawlor, PG, Gagnon, B, Mancini, ILet al. (2000b). Delirium as a predictor of survival in older patients with advanced cancer. Arch Int Med 160: 2866–2868.
Leslie, DL, Zhang, Y, Holford, TRet al. (2005). Premature death associated with delirium at 1-year follow-up. Arch Intern Med 165(14): 1657–1662.
Lipowski, ZJ (1990). Delirium: Acute Confusional States. New York: Oxford University Press.
Ljubisavljevic, V, Kelly, B (2003). Risk factors for development of delirium among oncology patients. Gen Hosp Psychiatry 25(5): 345–352.
Marcantonio, ER, Juarez, G, Goldman, Let al. (1994). The relationship of postoperative delirium with psychoactive medications. J Am Med Assoc 272(19): 1518–1522.
Massie, MJ, Holland, J, Glass, E (1983). Delirium in terminally ill cancer patients. Am J Psychiatry 140(8): 1048–1050.
Mayo-Smith, MF, Mayo-Smith, MF (1997). Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. J Am Med Assoc 278(2): 144–151.
Mazzocato, C, Stiefel, F, Buclin, T, Berney, A (2000). Psychopharmacology in supportive care of cancer: a review for the clinician: II Neuroleptics. Support Care Cancer (8)2: 89–97.
Mercadante, S, Bruera, E (2006). Opioid switching: a systematic and critical review. Cancer Treat Rev 32: 304–315.
Meyers, CA, Valentine, AD (1995). Neurological and psychiatric adverse effects of immunological therapy. CNS Drugs 3: 56–68.
Morita, T, Otani, H, Tsunoda, Jet al. (2000). Successful palliation of hypoactive delirium due to multi-organ failure by oral methylphenidate. Support Care Cancer 8(2): 134–137.
New, P (2001). Radiation injury to the nervous system. Curr Opinion Neurol 14(6): 725–734.
O'Keeffe, ST, Lavan, JN (1999). Clinical significance of delirium subtypes in older people. Age Ageing 28(2): 115–119.
Olin, J, Masand, P (1996). Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 37(1): 57–62.
Pereira, J, Bruera, E (2001). Depression with psychomotor retardation: diagnostic challenges and the use of psychostimulants. J Palliat Med 4(1): 15–21.
Platt, MM, Breitbart, W, Smith, Met al. (1994). Efficacy of neuroleptics for hypoactive delirium. J Neuropsychiatry Clin Neurosci 6(1): 66–67.
Prieto, JM, Blanch, J, Atala, Jet al. (2002). Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol 20(7): 1907–1917.
Raison, CL, Demetrashvili, M, Capuron, L, Miller, AH (2005). Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19(2): 105–123.
Reifler, BV (2000). A case of mistaken identity: pseudodementia is really predementia. J Am Geriatr Soc 48(5): 593–594.
Reischies, FM, Neu, P (2000). Comorbidity of mild cognitive disorder and depression – a neuropsychological analysis. Eur Arch Psychiatry Clin Neurosci 250(4): 186–193.
Ross, CA, Peyser, CE, Shapiro, I, Folstein, MF (1991). Delirium: phenomenologic and etiologic subtypes. Int Psychogeriatr 3(2): 135–147.
Rozans, M, Dreisbach, A, Lertora, JJ, Kahn, MJ (2002). Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol 20(1): 335–339.
Sarhill, N, Walsh, D, Nelson, KAet al. (2001). Assessment of delirium in advanced cancer: the use of the bedside confusion scale. Am J Hospice Palliat Care 18: 335–341.
Schagen, SB, Muller, MJ, Boogerd, W (2002). Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 9(13): 1387–1397.
Sood, A, Barton, DL, Loprinzi, CL (2006). Use of methylphenidate in patients with cancer. Am J Hospice Palliat Care 23(1): 35–40.
Trzepacz, PT (1994). A review of delirium assessment instruments. Gen Hosp Psychiatry 16(6): 397–405.
Trzepacz, PT (1996). Delirium. Advances in diagnosis, pathophysiology, and treatment. Psychiatrics Clin North Am 19(3): 429–448.
Trzepacz, PT, Baker, RW, Greenhouse, J (1988). A symptom rating scale for delirium. Psychiat Res 23(1): 89–97.
Tune, , Damlouji, NF, Holland, Aet al. (1981). Association of postoperative delirium with raised serum levels of anticholinergic drugs. Lancet 2(8248): 651–653.
Valentine, AD, Bickham, JG (2005). Delirium and substance withdrawal. In Shaw, A (ed.) Acute Care of the Cancer Patient (pp. 545–557). New York: Marcel Dekker.
Verstappen, CC, Heimans, JJ, Hoekman, K, Postma, TJ (2003). Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63(15): 1549–1563.
Visser, PJ, Verhey, FR, Ponds, RWet al. (2000). Distinction between preclinical Alzheimer's disease and depression. J Am Geriatr Soc 48(5): 479–484.
Wefel, JS, Lenzi, R, Theriault, RL, Davis, RN, Meyers, CA (2004). The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11): 2292–2299.